Histological evaluation of the skin tumours showed that 50% of the anti-IL-33-treated mice exhibited mild hyperplasia (grade I) (Fig. 3e), while only 25% were classified as SCC in situ (Fig. 3e). This evidence concerns the gene IL33 and skin neoplasm.